FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030257434> ?p ?o ?g. }

• W2030257434 endingPage "516" @default.
• W2030257434 startingPage "515" @default.
• W2030257434 abstract "Together, cancer and cardiac disease are the leading causes of death in North America. 1 Centers for Disease Control. Deaths and mortality. 2013. Available at: http://www.cdc.gov/nchs/fastats/deaths.htm Google Scholar Recognizing this, in 2010 a group of oncologists saw the need for cardiologists and oncologists to work together and suggested that this interdisciplinary collaboration be termed “cardio-oncology” or “onco-cardiology.” 2 Albini A. Pennesi G. Donatelli F. Cammarota R. De Flora S. Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102: 14-25 Crossref PubMed Scopus (573) Google Scholar Since then, this concept has evolved into a clinical discipline that focuses on the intersection of cardiac, oncologic, and hematologic disease. As a relatively young discipline, it has attracted a lot of recent attention. However, the need to understand this overlap between cancer and cardiovascular disease is not new but rather newly recognized, coinciding with the enhanced survival offered by modern cancer therapy. Acute as well as long-term cardiac sequelae of established and evolving cancer therapy are now both clinically apparent and relevant. Although cardiotoxicity associated with cancer therapy can include a variety of concerns, such as hypertension, ischemia, or arrhythmia, it is left ventricular (LV) dysfunction that has been a major focus of investigation in this area. After all, the latter is a clinical entity for which we have well-established diagnostic tools, such as echocardiography, along with a well-defined and validated therapeutic strategy in the form of angiotensin-converting enzymes and β-blockers. However, it is clear that overt LV dysfunction, as evidenced by a reduced ejection fraction (EF), is a rather late manifestation of cardiotoxicity. Therefore, more recent attention has focused on harnessing speckle-tracking echocardiography to evaluate myocardial mechanics, with global longitudinal strain (GLS) as an indicator of subclinical LV dysfunction. 3 Negishi K. Negishi T. Hare J.L. Haluska B.A. Plana J.C. Marwick T.H. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013; 26: 493-498 Abstract Full Text Full Text PDF PubMed Scopus (325) Google Scholar , 4 Thavendiranathan P. Poulin F. Lim K.D. Plana J.C. Woo A. Marwick T.H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014; 63: 2751-2768 Crossref PubMed Scopus (694) Google Scholar , 5 Sawaya H. Sebag I.A. Plana J.C. Januzzi J.L. Ky B. Tan T.C. et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with athracyclines, taxanes and trastuzumab. Circ Cardiovasc Imaging. 2012; 5: 596-603 Crossref PubMed Scopus (560) Google Scholar Indeed, a recently published expert consensus document on the imaging evaluation of patients during and after cancer therapy, 6 Plana J.C. Galderisi M. Barac A. Ewer M.S. Ky B. Scherrer-Crosbie M. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27: 911-939 Abstract Full Text Full Text PDF PubMed Scopus (804) Google Scholar defines cardiotoxicity as a symptomatic or asymptomatic decline in LV EF of >10% to a value < 53%. However, in addition to LV EF determination, this document also suggests incorporating GLS in the echocardiographic protocol, with a reduction in GLS of >15% from baseline being meaningful in a patient at risk for cardiotoxicity. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and TrastuzumabJournal of the American Society of EchocardiographyVol. 28Issue 5PreviewTrastuzumab, a HER2 monoclonal antibody, has transformed the prognosis of patients with the aggressive HER2-positive breast cancer type. Trastuzumab augments the cardiotoxic effects of anthracyclines, but its effect is thought to be at least partially reversible. The objective of this study was to examine the time trends of left ventricular (LV) size and function in a cohort of women treated with anthracyclines and trastuzumab. Full-Text PDF" @default.
• W2030257434 created "2016-06-24" @default.
• W2030257434 creator A5070302668 @default.
• W2030257434 creator A5080700451 @default.
• W2030257434 date "2015-05-01" @default.
• W2030257434 modified "2023-09-27" @default.
• W2030257434 title "Caring for the Cardio-Oncology Patient: Straining to Foresee the Future" @default.
• W2030257434 cites W1968148627 @default.
• W2030257434 cites W2087476788 @default.
• W2030257434 cites W2090295140 @default.
• W2030257434 cites W2095689312 @default.
• W2030257434 cites W2120694824 @default.
• W2030257434 cites W2133304247 @default.
• W2030257434 cites W2133528707 @default.
• W2030257434 cites W2141469083 @default.
• W2030257434 cites W2154066911 @default.
• W2030257434 cites W2170514599 @default.
• W2030257434 cites W36650246 @default.
• W2030257434 doi "https://doi.org/10.1016/j.echo.2015.03.007" @default.
• W2030257434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25953465" @default.
• W2030257434 hasPublicationYear "2015" @default.
• W2030257434 type Work @default.
• W2030257434 sameAs 2030257434 @default.
• W2030257434 citedByCount "2" @default.
• W2030257434 countsByYear W20302574342017 @default.
• W2030257434 countsByYear W20302574342021 @default.
• W2030257434 crossrefType "journal-article" @default.
• W2030257434 hasAuthorship W2030257434A5070302668 @default.
• W2030257434 hasAuthorship W2030257434A5080700451 @default.
• W2030257434 hasConcept C121608353 @default.
• W2030257434 hasConcept C126322002 @default.
• W2030257434 hasConcept C143998085 @default.
• W2030257434 hasConcept C177713679 @default.
• W2030257434 hasConcept C2776694085 @default.
• W2030257434 hasConcept C2778233292 @default.
• W2030257434 hasConcept C2779134260 @default.
• W2030257434 hasConcept C2983331546 @default.
• W2030257434 hasConcept C71924100 @default.
• W2030257434 hasConceptScore W2030257434C121608353 @default.
• W2030257434 hasConceptScore W2030257434C126322002 @default.
• W2030257434 hasConceptScore W2030257434C143998085 @default.
• W2030257434 hasConceptScore W2030257434C177713679 @default.
• W2030257434 hasConceptScore W2030257434C2776694085 @default.
• W2030257434 hasConceptScore W2030257434C2778233292 @default.
• W2030257434 hasConceptScore W2030257434C2779134260 @default.
• W2030257434 hasConceptScore W2030257434C2983331546 @default.
• W2030257434 hasConceptScore W2030257434C71924100 @default.
• W2030257434 hasIssue "5" @default.
• W2030257434 hasLocation W20302574341 @default.
• W2030257434 hasLocation W20302574342 @default.
• W2030257434 hasOpenAccess W2030257434 @default.
• W2030257434 hasPrimaryLocation W20302574341 @default.
• W2030257434 hasRelatedWork W2057255767 @default.
• W2030257434 hasRelatedWork W2438865343 @default.
• W2030257434 hasRelatedWork W2557376112 @default.
• W2030257434 hasRelatedWork W2755075042 @default.
• W2030257434 hasRelatedWork W2912579031 @default.
• W2030257434 hasRelatedWork W2915875709 @default.
• W2030257434 hasRelatedWork W3130188888 @default.
• W2030257434 hasRelatedWork W3163237901 @default.
• W2030257434 hasRelatedWork W4282926119 @default.
• W2030257434 hasRelatedWork W4323360657 @default.
• W2030257434 hasVolume "28" @default.
• W2030257434 isParatext "false" @default.
• W2030257434 isRetracted "false" @default.
• W2030257434 magId "2030257434" @default.
• W2030257434 workType "article" @default.